Volume 99, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



As dengue causes about 4,000 symptomatic nonfatal episodes for every dengue death globally, quantitative disability assessments are critical to assess the burden of dengue and the cost-effectiveness of dengue control interventions. This systematic analysis of disability or quality of life lost from a symptomatic nonfatal dengue episode combined a systematic literature review, statistical modeling, and probabilistic sensitivity analyses. We conceptualized a dengue episode as having two phases: acute and persistent symptoms. Our estimates for the acute phase, consisting of onset and recovery periods and defined as the first 20 days (0.054 year), were based on literature review. We searched PubMed, POPLINE, EconLit, Google Scholar, scientific conferences, and other sources, for “dengue” plus “quality of life” or related terms. From 4,322 initial entries, six met our criteria (original studies with empirical data). The median disability-adjusted life year (DALY) burden for the acute phase was 0.011 (95% certainty interval [CI]: 0.006–0.015) for ambulatory episodes, 0.015 (CI: 0.010–0.020) for hospitalized episodes, and 0.012 (CI: 0.006–0.019) overall. Using literature reviews about persistent dengue, we estimated that 34% of episodes experienced persistent symptoms with a median duration of symptoms of 0.087 (CI: 0.040–0.359) year, which resulted in median DALYs of 0.019 (CI: 0.008–0.082). Thus, the overall median DALY burden was 0.031 (CI: 0.017–0.092) for ambulatory episodes, 0.035 (CI: 0.024–0.096) for hospitalized episodes, and 0.032 (CI: 0.018–0.093) overall. Our dengue-specific burden of a dengue episode was 2.1 times the 2013 Global Burden of Disease estimate. These literature-based estimates provide an empirical summary for policy and cost-effectiveness analyses.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL, Farlow AW, Scott TW, Hay SI, , 2012. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 6: e1760. [Google Scholar]
  2. Stanaway JD, 2016. The global burden of dengue: an analysis from the Global Burden of Disease study 2013. Lancet Infect Dis 16: 712723. [Google Scholar]
  3. Zeckhauser R, Shepard DS, , 1976. Where new for saving lives? Law Contemp Probl 40: 545. [Google Scholar]
  4. Sassi F, , 2006. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan 21: 402408. [Google Scholar]
  5. Wong JG, Gan VC, Ng EL, Leo YS, Chan SP, Choo R, Lye DC, , 2014. Self-reported pain intensity with the numeric reporting scale in adult dengue. PLoS One 9: e96514. [Google Scholar]
  6. Garcia G, 2011. Long-term persistence of clinical symptoms in dengue-infected persons and its association with immunological disorders. Int J Infect Dis 15: e38e43. [Google Scholar]
  7. Gonzalez D, Martinez R, Castro O, Serrano T, Portela D, Vazquez S, Kouri G, Guzman MG, , 2005. Evaluation of some clinical, humoral and imagenological parameters in patients of dengue haemorrhagic fever six months after acurte illness. Dengue Bull 29: 7984. [Google Scholar]
  8. Tiga DC, Undurraga EA, Ramos-Castaneda J, Martinez-Vega RA, Tschampl CA, Shepard DS, , 2016. Persistent symptoms of dengue: estimates of the incremental disease and economic burden in Mexico. Am J Trop Med Hyg 94: 10851089. [Google Scholar]
  9. Lum LC, Suaya JA, Tan LH, Sah BK, Shepard DS, , 2008. Quality of life of dengue patients. Am J Trop Med Hyg 78: 862867. [Google Scholar]
  10. Salomon JA, 2015. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health 3: e712e723. [Google Scholar]
  11. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD, , 2016. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis 16: 935941. [Google Scholar]
  12. Kim DD, Basu A, Duffy SQ, Zarkin GA, , 2017. Worked example 1: the cost-effectiveness of treatments for individuals with alcohol use disorders: a reference case analysis. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press, 385–430.
  13. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P, , 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535. [Google Scholar]
  14. Armien B, Suaya JA, Quiroz E, Sah BK, Bayard V, Marchena L, Campos C, Shepard DS, , 2008. Clinical characteristics and national economic cost of the 2005 dengue epidemic in Panama. Am J Trop Med Hyg 79: 364371. [Google Scholar]
  15. Martelli CM, Nascimento NE, Suaya JA, Siqueira JB, Jr. Souza WV, Turchi MD, Guilarde AO, Peres JB, Jr. Shepard DS, , 2011. Quality of life among adults with confirmed dengue in Brazil. Am J Trop Med Hyg 85: 732738. [Google Scholar]
  16. Nguyen NM, 2013. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 207: 14421450. [Google Scholar]
  17. Shepard DS, Zeng W, Halasa YA, Durand L, Coudeville L, , 2017. Impact of a Dengue Episode on Quality of Life or DALYs: Systematic Review. ISPOR 22nd Annual International Meeting, May 20–24, 2017, Boston, MA. Available at: https://www.ispor.org/research_pdfs/55/pdffiles/PIN50.pdf. Accessed March 19, 2018.
  18. Whitehorn J, 2016. Lovastatin for the treatment of adult patients with dengue: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 62: 468476. [Google Scholar]
  19. Suaya JA, 2009. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 80: 846855. [Google Scholar]

Data & Media loading...

Supplemental appendix

  • Received : 11 Apr 2018
  • Accepted : 31 Jul 2018
  • Published online : 01 Oct 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error